Cytek director granted options and 33,333 RSUs
Cytek Biosciences, Inc. director Richard Chin reported receiving new equity awards as part of his board compensation.
Rhea-AI Filing Summary
Cytek Biosciences, Inc. director Richard Chin reported receiving new equity awards as part of his board compensation. He was granted an option for 18,261 shares of common stock at an exercise price of $4.05 per share, expiring on June 10, 2036. He also received 33,333 restricted stock units, each representing one share of common stock. Both the option and RSU award vest 100% on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting, if that meeting is held in June 2027. These are compensation-related grants, not open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 51,594 shares
Grant/Award
2 txns
Insider
Chin Richard
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Units | 33,333 | $0.00 | $0.00 |
| Grant/Award | Director Stock Option (right to buy) | 18,261 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 33,333 contracts (Direct);
Director Stock Option (right to buy) — 18,261 contracts (Direct)
Footnotes (3)
- F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
- F3. 100% of the shares subject to the option shall vest on the earlier of June 10, 2027 and the date of the Issuer's 2027 annual meeting of stockholders (provided such meeting is held in June 2027).
Key Figures
Stock options granted: 18,261 options
Option exercise price: $4.05 per share
Option expiration: June 10, 2036
+4 more
7 metrics
Stock options granted
18,261 options
Director option grant on June 10, 2026
Option exercise price
$4.05 per share
Director stock option strike price
Option expiration
June 10, 2036
Director stock option term end date
RSUs granted
33,333 RSUs
Restricted stock unit award on June 10, 2026
RSU vesting date
June 10, 2027 (or 2027 meeting)
Full vesting on earlier of June 10, 2027 or 2027 annual meeting in June
Shares underlying option
18,261 shares
Common stock issuable upon exercise of option
Shares underlying RSUs
33,333 shares
Common stock represented by RSU award
Key Terms
Restricted Stock Units, contingent right, vest, Director Stock Option, +1 more
5 terms
Restricted Stock Units financial
"Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of the Issuer's common stock"
vest financial
"100% of the shares subject to the RSU Award shall vest on the earlier of June 10, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Director Stock Option financial
"Director Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price": "4.0500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Cytek Biosciences (CTKB) director Richard Chin report?
Richard Chin reported receiving equity awards, not trading stock in the market. He was granted 18,261 stock options and 33,333 restricted stock units as director compensation, all tied to Cytek Biosciences common shares and subject to future vesting conditions.
How many Cytek Biosciences (CTKB) stock options did Richard Chin receive and at what price?
Richard Chin received an option covering 18,261 Cytek Biosciences common shares. The option has an exercise price of $4.05 per share and expires on June 10, 2036, providing a long-dated right to buy shares if the vesting conditions are satisfied.
What are the terms of Richard Chin’s restricted stock units in Cytek Biosciences (CTKB)?
He received 33,333 restricted stock units, each representing a contingent right to one Cytek Biosciences common share. These RSUs vest 100% on the earlier of June 10, 2027 or the 2027 annual stockholder meeting, provided that meeting occurs in June 2027.
When do Richard Chin’s Cytek Biosciences (CTKB) equity awards vest?
Both the stock option and RSU grant fully vest on the earlier of June 10, 2027 or the date of Cytek’s 2027 annual meeting of stockholders, if that meeting is held in June 2027. Vesting must occur before he can realize full share benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
